Drugs / Rituximab
Rituximab
Drug FDA approvedMarketed as Rituxan
CD20-directed cytolytic monoclonal antibody·First approved·1997·1 brand
- Registered trials
- 1662
- Ongoing
- 393/ 24%
- Completed
- 824
- Indications
- 4
Approved indications by brand
| Brand | Indication |
|---|---|
| Rituxan | Non-Hodgkin's lymphoma |
| Chronic lymphocytic leukemia | |
| Rheumatoid arthritis in combination with methotrexate after inadequate response to TNF antagonists | |
| Granulomatosis with polyangiitis and microscopic polyangiitis in combination with glucocorticoids |
Clinical trial landscape
1662 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 766 | 175 | 385 | |
| Phase 3 | 291 | 82 | 137 | |
| Phase 1 | 222 | 54 | 111 | |
| Phase 1/2 | 198 | 49 | 90 | |
| Phase 4 | 51 | 10 | 27 | |
| Not applicable | 44 | 7 | 22 | |
| Unknown | 40 | 6 | 26 | |
| Phase 2/3 | 35 | 8 | 18 | |
| Early Phase 1 | 15 | 2 | 8 | |
| All phases | 1662 | 393 | 824 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Targets CD20 on pre-B and mature B lymphocytes and mediates B-cell lysis via CDC and ADCC.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.